Related Experiment Videos
Statin-fibrate combination: therapy for hyperlipidemia: a review
A S Wierzbicki1, D P Mikhailidis, R Wray
1Department of Chemical Pathology, St. Thomas' Hospital, London, UK. Anthony.Wierzbicki@kcl.ac.uk
Current Medical Research and Opinion
|June 20, 2003
Summary
Fibrate and statin combination therapy is an option for high-risk patients with hyperlipidaemia when other treatments fail. Careful patient selection and monitoring are crucial due to potential rhabdomyolysis risks.
Area of Science:
- Cardiology
- Pharmacology
- Metabolic Disorders
Background:
- Statins and fibrates are primary treatments for hyperlipidaemia and vascular event prevention.
- Combination therapy was previously restricted due to rhabdomyolysis reports, mainly with gemfibrozil and specific statins.
Purpose of the Study:
- To review existing studies on statin + fibrate combination therapy.
- To outline indications, contraindications, and optimal protocols for this combination therapy.
Main Methods:
- Review of published literature on statin and fibrate combination therapy.
- Analysis of patient profiles, lipid targets, and safety monitoring protocols.
Main Results:
- Combination therapy is indicated when monotherapy or other drug additions fail to meet lipid targets.
- Reserved for high-risk patients with specific mixed hyperlipidaemia profiles (high LDL, low HDL, high triglycerides).
- Requires normal organ function, exclusion of interacting medications, and use of short half-life drugs.
Conclusions:
- Fibrate + statin therapy is a viable option for select high-risk patients with hyperlipidaemia.
- Further long-term studies are needed to confirm safety and efficacy regarding vascular endpoints.